Cargando…
Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature
Hemolytic uremic syndrome (HUS) is a rare thrombotic complication characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS may be caused by several different conditions, including infection, malignancy, and chemotherapeutic agents, such as mitomyc...
Ejemplares similares
-
Gemcitabine induced hemolytic uremic syndrome
por: Sadjadi, Seyed-Ali, et al.
Publicado: (2012) -
FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
por: Cho, In Rae, et al.
Publicado: (2020) -
A case of hemolytic uremic syndrome preceded by intussusception
por: Ko, Eun Young, et al.
Publicado: (2011) -
Shiga toxin-associated hemolytic uremic syndrome complicated by intestinal perforation in a child with typical hemolytic uremic syndrome
por: Chang, Hye Jin, et al.
Publicado: (2014) -
Eculizumab in the Treatment of Gemcitabine-Induced Atypical Hemolytic Uremic Syndrome
por: Azad, Farhan, et al.
Publicado: (2023)